UBS lowered the firm’s price target on Moderna (MRNA) to $108 from $140 and keeps a Buy rating on the shares following a model review.

Street Talk understands wealth advisers are fired up about a global edict that will keep them wedded to the Credit Suisse ...

UBS must review and improve its plans for an emergency to increase its options should there be a risk of insolvency, Swiss ...

Swiss financial regulator FINMA has urged UBS to enhance its emergency measures to improve readiness in potential insolvency ...

Both Hardin and O’Hara join UBS’s Integra Partners, a private wealth management group led by advisors Vicente Del Rio, Brian ...

BASF SE (ETR:BASFN) has been downgraded by UBS to a "neutral" rating  from a "buy,” signaling a shift in investor sentiment based on several macroeconomic and industry-specific challenges the company ...

Jim Kosan, financial advisor for ultra high net worth clients, switches from Morgan Stanley to UBS, joins Riverside office. Pat Lizza welcomes him.

Five UBS Wealth Management USA financial advisers based in the firm’s Pacific Desert Market have been named to the Forbes Top ...

Reliance Industries experienced a 5% YoY drop in Q2FY25 net profit to ₹16,563 crore, largely from its O2C segment. Yet, ...

UBS is divesting a portion of the Credit Suisse business it acquired last year by selling the fallen bank’s 50% stake in ...

UBS reviews the order execution principles once a year. The review also includes the use of intermediaries. In addition, UBS will review these principles if there are indications that UBS's ability to ...